CA2331408A1 - Fatty analogues for the treatment of obesity, hypertension and fatty liver - Google Patents

Fatty analogues for the treatment of obesity, hypertension and fatty liver Download PDF

Info

Publication number
CA2331408A1
CA2331408A1 CA002331408A CA2331408A CA2331408A1 CA 2331408 A1 CA2331408 A1 CA 2331408A1 CA 002331408 A CA002331408 A CA 002331408A CA 2331408 A CA2331408 A CA 2331408A CA 2331408 A1 CA2331408 A1 CA 2331408A1
Authority
CA
Canada
Prior art keywords
fatty
obesity
hypertension
treatment
analogues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002331408A
Other languages
French (fr)
Other versions
CA2331408C (en
Inventor
Rolf Berge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Life Science Nutrition AS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2331408A1 publication Critical patent/CA2331408A1/en
Application granted granted Critical
Publication of CA2331408C publication Critical patent/CA2331408C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

The present invention relates to novel fatty acid analogous of the general forumla I: CH3-[CH2]m-[X i-CH2]n-COOR, as defined in the specification, which can be used for the treatment and/or prevention of obesity, fatty liver and hypertension. Further, the invention relates to a nutritional composition comprising such fatty acid analogues, and a method for reducing the total weight, or the amount of adipose tissue in an animal. The invention also relates to a method for improving the quality of product such as meat, milk and eggs.
CA002331408A 1998-05-08 1999-04-23 Fatty analogues for the treatment of obesity, hypertension and fatty liver Expired - Fee Related CA2331408C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/NO1998/000143 WO1999058120A1 (en) 1998-05-08 1998-05-08 USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
NOPCT/NO98/00143 1998-05-08
PCT/NO1999/000135 WO1999058121A1 (en) 1998-05-08 1999-04-23 Novel fatty analogues for the treatment of obesity, hypertension and fatty liver

Publications (2)

Publication Number Publication Date
CA2331408A1 true CA2331408A1 (en) 1999-11-18
CA2331408C CA2331408C (en) 2008-10-21

Family

ID=19907879

Family Applications (3)

Application Number Title Priority Date Filing Date
CA002331395A Expired - Fee Related CA2331395C (en) 1998-05-08 1999-04-23 Fatty acid analogues for the treatment of diabetes
CA002331408A Expired - Fee Related CA2331408C (en) 1998-05-08 1999-04-23 Fatty analogues for the treatment of obesity, hypertension and fatty liver
CA002331393A Expired - Fee Related CA2331393C (en) 1998-05-08 1999-05-07 Fatty acid analogues for the treatment of primary and secondary restenosis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA002331395A Expired - Fee Related CA2331395C (en) 1998-05-08 1999-04-23 Fatty acid analogues for the treatment of diabetes

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002331393A Expired - Fee Related CA2331393C (en) 1998-05-08 1999-05-07 Fatty acid analogues for the treatment of primary and secondary restenosis

Country Status (18)

Country Link
US (4) US6365628B1 (en)
EP (5) EP1075258B1 (en)
JP (3) JP2002514595A (en)
KR (3) KR100701502B1 (en)
CN (3) CN1245157C (en)
AT (5) ATE247464T1 (en)
AU (4) AU7240398A (en)
BR (2) BR9910296A (en)
CA (3) CA2331395C (en)
DE (5) DE69909775T2 (en)
DK (3) DK1075259T3 (en)
ES (3) ES2204142T3 (en)
HK (3) HK1034911A1 (en)
NO (3) NO20005461L (en)
NZ (3) NZ508045A (en)
PT (2) PT1075259E (en)
RU (3) RU2219920C2 (en)
WO (4) WO1999058120A1 (en)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7240398A (en) * 1998-05-08 1999-11-29 Rolf Berge Use of non-beta-oxidizable fatty acid analogues for treatment of syndrome-x conditions
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
AUPQ291499A0 (en) * 1999-09-17 1999-10-07 Women's And Children's Hospital Adelaide Novel nitro and sulphur containing compounds
AU784588B2 (en) * 1999-09-17 2006-05-04 Peplin Biolipids Pty Ltd Anti-inflammatory nitro- and thia- fatty acids
JP2003514855A (en) * 1999-10-13 2003-04-22 チャコン，マルコ，エー． Therapeutic intervention mimicking the effects of calorie restriction
NO328803B1 (en) * 2000-03-03 2010-05-18 Thia Medica New fatty acid analogues
NO20003591L (en) * 2000-07-13 2002-01-14 Thia Medica As Fatty acid analogues for the treatment of cancer
NO20006008L (en) 2000-11-28 2002-05-29 Thia Medica As Fatty acid analogues for the treatment of inflammatory and autoimmune diseases
DE10115740A1 (en) * 2001-03-26 2002-10-02 Ulrich Speck Preparation for restenosis prophylaxis
IL142535A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
US6908632B1 (en) 2002-04-19 2005-06-21 Pharmanex, Llc Blood glucose modulating compositions and methods
SI1547614T1 (en) * 2002-05-28 2011-04-29 Ajinomoto Kk Medicinal composition for inhibiting the expression of atp-citrate lyase and use thereof
RU2331649C2 (en) * 2002-06-20 2008-08-20 Ай-Си Ви-И-Си Лимитед Sulphur containing phospholipid derivatives, pharmaceutical compositions containing them, their use in treating diseases and method of obtaining them
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US7045547B2 (en) * 2002-08-20 2006-05-16 University Of Delaware Acyl-CoA dehydrogenase allenic inhibitors
KR20050033662A (en) 2002-09-06 2005-04-12 얀센 파마슈티카 엔.브이. Heterocyclic compounds
AU2003272738B2 (en) * 2002-09-27 2010-04-01 Martek Biosciences Corporation Docosahexaenoic acid for improved glycemic control
NZ539106A (en) * 2002-10-10 2007-02-23 Yeda Res & Dev Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents
FR2850650B1 (en) * 2003-01-31 2005-03-25 Genfit S A THERAPEUTIC USE OF ACYLGLYCEROLS AND THEIR NITROGEN AND SULFUR ANALOGUES
FR2850869B1 (en) * 2003-02-12 2005-03-25 Genfit S A USES OF ACYLATED AMINOPROPANEDIOLS AND THEIR NITROGEN AND SULFUR ANALOGUES
CA2515368A1 (en) 2003-02-13 2004-08-26 Luciano Rossetti Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus
US20090215895A1 (en) * 2004-01-30 2009-08-27 Peplin Biolipids Pty Ltd Therapeutic and carrier molecules
US8137994B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US20050215558A1 (en) * 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
US8137993B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
WO2005119250A1 (en) * 2004-05-28 2005-12-15 Janssen Pharmaceutica N.V. New intravenous drug administration and blood sampling model in the awake rat
DE102004034640A1 (en) 2004-07-16 2006-02-16 Institut für Molekular- und Systemmedizin Method for systemic biocorrection of an organism
ES2660700T3 (en) * 2004-07-19 2018-03-23 Bergen Teknologioverføring As Composition comprising vegetable and / or fish oils and non-oxidizable fatty acid entities
NO324534B1 (en) * 2004-07-19 2007-11-19 Thia Medica As Material prepared from a combination of non-β-oxidizable fatty acid analogues and a plant oil or fish oil and uses thereof
WO2006041922A2 (en) * 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents and methods for administration to the central nervous system
WO2006083439A2 (en) * 2004-12-28 2006-08-10 The Research Foundation Of State University Of New York At Buffalo Method for lowering serum homocysteine
US20070026079A1 (en) * 2005-02-14 2007-02-01 Louis Herlands Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels
WO2006117664A1 (en) * 2005-05-04 2006-11-09 Pronova Biopharma Norge As New dha derivatives and their use as medicaments
US7586003B2 (en) * 2005-07-14 2009-09-08 Zinpro Corporation Derivatives of seleno-amino acids
NO20053519L (en) * 2005-07-18 2007-01-19 Thia Medica As Use of compounds comprising fatty acids
NO20055541L (en) * 2005-11-23 2007-05-24 Berge Biomed As Use of fatty acid analogues
GB0605900D0 (en) * 2006-03-23 2006-05-03 Lipigen As Modulators of nuclear receptors
US20080085293A1 (en) * 2006-08-22 2008-04-10 Jenchen Yang Drug eluting stent and therapeutic methods using c-Jun N-terminal kinase inhibitor
BRPI0718420A2 (en) 2006-10-20 2013-11-12 Cpd Llc RESEARCH METHOD OF INCRETIN EFFECT
CA2667150A1 (en) * 2006-11-01 2008-11-06 Pronova Biopharma Norge As Omega-3 lipid compounds
CA2667211A1 (en) * 2006-11-01 2008-05-08 Pronova Biopharma Norge As Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (ppar)
US20080221115A1 (en) * 2007-02-26 2008-09-11 Liat Hayardeny-Nisimov Use of long-chain alcohol derivatives for the treatment of alopecia areata
WO2008106092A1 (en) * 2007-02-26 2008-09-04 Yeda Research And Development Co. Ltd. Enantiomers of amino-phenyl-acetic acid octadec- 9- (z) enyl ester, their salts and their uses
CA2702577A1 (en) 2007-10-15 2009-04-23 Jbs United, Inc. Method for increasing performance of offspring
KR20100100818A (en) * 2007-10-31 2010-09-15 프로노바 바이오파마 노르지 에이에스 New dha derivatived and their use as medicaments
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
RU2502727C2 (en) * 2008-04-29 2013-12-27 Ф.Хоффманн-Ля Рош Аг 4-trimethylammonio-butyrates as cpt2 inhibitors
EP2147910A1 (en) * 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Novel lipid compounds
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
EP2334234A4 (en) 2008-09-19 2013-03-20 Tandem Diabetes Care Inc Solute concentration measurement device and related methods
PT2427415T (en) 2009-05-08 2019-05-31 Basf As Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
CA2921304C (en) 2009-07-30 2018-06-05 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
CN103237546B (en) 2010-07-28 2016-06-08 生命科技公司 The antiviral compound that contains azide
US20120028335A1 (en) 2010-07-28 2012-02-02 Life Technologies Corporation Anti-viral azide-containing compounds
KR102265409B1 (en) 2010-11-05 2021-06-16 바스프 에이에스 Methods of treatment using lipid compounds
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
KR102213143B1 (en) 2013-02-28 2021-02-08 바스프 에이에스 A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
CA2904898C (en) 2013-03-11 2019-10-15 Jan Remmereit Lipid compositions containing bioactive fatty acids
WO2014140934A2 (en) 2013-03-11 2014-09-18 Life Science Nutrition As Natural lipids containing non-oxidizable fatty acids
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
RU2522224C1 (en) * 2013-08-06 2014-07-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Уральская государственная академия ветеринарной медицины" Method of treatment of acute hepatosis in cats
ES2787223T3 (en) 2014-11-07 2020-10-15 Univ Minnesota Salts and compositions useful for treating diseases
AU2016256552B2 (en) 2015-04-28 2021-04-01 Pronova Biopharma Norge As Use of structurally enhanced fatty acids containing sulphur for preventing and/or treating non-alcoholic steatohepatitis
US10492141B2 (en) 2015-11-17 2019-11-26 Tandem Diabetes Care, Inc. Methods for reduction of battery usage in ambulatory infusion pumps
JP7312184B2 (en) * 2017-10-23 2023-07-20 エピトラッカー インコーポレイテッド Fatty acid analogues and their use in treating symptoms associated with metabolic syndrome
US11925614B2 (en) 2017-12-06 2024-03-12 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
JP7404382B2 (en) * 2019-03-04 2023-12-25 エピトラッカー インコーポレイテッド Fatty acid analogs and their use in the treatment of cognitive dysfunction, behavioral symptoms and chronic pain

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59175425A (en) * 1983-03-25 1984-10-04 Otsuka Pharmaceut Co Ltd Vessel strengthening agent
GB8813012D0 (en) * 1988-06-02 1988-07-06 Norsk Hydro As Non-b-oxidizable fatty acid analogues to reduce concentration of cholesterol & triglycerides in blood of mammals
US6063581A (en) * 1992-01-22 2000-05-16 Axis-Shield Asa Immunoassay for homocysteine
WO1996040098A2 (en) * 1995-06-07 1996-12-19 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
NO952796D0 (en) * 1995-07-14 1995-07-14 Rolf Berge Fatty acid analogues with non-oxidizable B-site, preparation and use in crepes
ATE221324T1 (en) * 1996-11-20 2002-08-15 Nutricia Nv FAT-CONTAINING NUTRITIONAL COMPOSITION FOR THE TREATMENT OF METABOLIC SYNDROME
AU7240398A (en) * 1998-05-08 1999-11-29 Rolf Berge Use of non-beta-oxidizable fatty acid analogues for treatment of syndrome-x conditions

Also Published As

Publication number Publication date
ATE306916T1 (en) 2005-11-15
US6365628B1 (en) 2002-04-02
AU4936699A (en) 1999-11-29
WO1999058123A3 (en) 2000-03-09
HK1034911A1 (en) 2001-11-09
CN1244323C (en) 2006-03-08
KR100701502B1 (en) 2007-04-02
CA2331408C (en) 2008-10-21
NO20005463D0 (en) 2000-10-30
AU762792B2 (en) 2003-07-03
NO20005463L (en) 2001-01-08
CA2331393A1 (en) 1999-11-18
RU2223095C2 (en) 2004-02-10
DE69932864D1 (en) 2006-09-28
CA2331393C (en) 2009-08-11
ATE245416T1 (en) 2003-08-15
JP5057003B2 (en) 2012-10-24
JP4465672B2 (en) 2010-05-19
AU5451799A (en) 1999-11-29
WO1999058121A1 (en) 1999-11-18
KR20010043316A (en) 2001-05-25
DK1075260T3 (en) 2006-02-06
CN1302204A (en) 2001-07-04
ES2204142T3 (en) 2004-04-16
EP1075258A1 (en) 2001-02-14
KR20010043314A (en) 2001-05-25
CA2331395A1 (en) 1999-11-18
WO1999058123A2 (en) 1999-11-18
EP1075260A2 (en) 2001-02-14
AU7240398A (en) 1999-11-29
JP2002514595A (en) 2002-05-21
DE69909775T2 (en) 2004-06-03
AU762790B2 (en) 2003-07-03
EP1075259B1 (en) 2003-07-23
DK1075259T3 (en) 2003-11-03
NO20005461L (en) 2001-01-08
PT1075259E (en) 2003-12-31
WO1999058120A1 (en) 1999-11-18
DE69910559T2 (en) 2004-06-17
US7026356B2 (en) 2006-04-11
NO20005461D0 (en) 2000-10-30
NZ508045A (en) 2003-08-29
EP1075258B1 (en) 2003-08-20
KR20010043315A (en) 2001-05-25
AU761355B2 (en) 2003-06-05
BR9910296A (en) 2002-01-15
KR100701503B1 (en) 2007-04-02
AU4936799A (en) 1999-11-29
EP1285652A1 (en) 2003-02-26
US20020198259A1 (en) 2002-12-26
EP1075260B1 (en) 2005-10-19
HK1034912A1 (en) 2001-11-09
ATE247464T1 (en) 2003-09-15
BR9910297A (en) 2002-01-02
ES2207253T3 (en) 2004-05-16
DE69932645D1 (en) 2006-09-14
EP1075259A1 (en) 2001-02-14
HK1034909A1 (en) 2001-11-09
KR100822077B1 (en) 2008-04-14
DE69910559D1 (en) 2003-09-25
ATE336239T1 (en) 2006-09-15
CA2331395C (en) 2008-10-14
NZ508046A (en) 2003-08-29
RU2221558C2 (en) 2004-01-20
WO1999058122A1 (en) 1999-11-18
DK1075258T3 (en) 2003-12-01
DE69927805T2 (en) 2006-07-06
PT1075258E (en) 2004-01-30
NO333143B1 (en) 2013-03-18
CN1223343C (en) 2005-10-19
CN1245157C (en) 2006-03-15
RU2219920C2 (en) 2003-12-27
US6441036B1 (en) 2002-08-27
CN1300212A (en) 2001-06-20
ATE334666T1 (en) 2006-08-15
NO20005462D0 (en) 2000-10-30
DE69927805D1 (en) 2006-03-02
EP1285652B1 (en) 2006-08-16
JP2002514596A (en) 2002-05-21
NO20005462L (en) 2001-01-08
JP2002514594A (en) 2002-05-21
NZ508047A (en) 2003-05-30
DE69909775D1 (en) 2003-08-28
EP1284139B1 (en) 2006-08-02
US6417232B1 (en) 2002-07-09
EP1284139A1 (en) 2003-02-19
ES2251218T3 (en) 2006-04-16
CN1300211A (en) 2001-06-20

Similar Documents

Publication Publication Date Title
CA2331408A1 (en) Fatty analogues for the treatment of obesity, hypertension and fatty liver
WO1995022906A3 (en) Food composition comprising a chocolate finger or shell and an optionally fermented dairy filling
CA2283488A1 (en) Method of increasing fat firmness and improving meat quality in animals
EP0703911A1 (en) Secondary amines as antidiabetic and antiobesity agents
HUP0102783A2 (en) Process and product for promoting weight loss in overweight dogs
DE69912934D1 (en) MULTIPLE FOOD, METHOD FOR THE PRODUCTION AND USE THEREOF
MXPA05002456A (en) Cooking cream.
CA2151296A1 (en) Fermented food product for animals
CA2261052A1 (en) Flexible partially cooked dough composition
WO1999048384A3 (en) Food containing biotin and other b vitamins
NZ314485A (en) stress-relieving livestock food containing yeast and glutathione
CA2522824A1 (en) Low cholesterol, functional animal muscle protein composition and process
CA2353451A1 (en) Method of increasing fat firmness and improving meat quality in animals
GB9712420D0 (en) Food
ATE234024T1 (en) MEAT PRODUCT WITH YOGURT AND METHOD FOR PRODUCING IT
AU1453401A (en) Compositions and methods for calcium fortification of dairy products and oleaginous foods
WO2002063948A3 (en) Poultry feed supplement for increasing poultry-based meat weight
EP1084621A3 (en) Salting agent for food processing
FR2765078B1 (en) METHOD FOR IMPROVING THE EFFECTIVENESS OF A PROBIOTIC, PREPARATION OF FOOD ADDITIVES AND ANIMAL FEED CONTAINING IT
HUP0202388A3 (en) Method and composition for regulating gut motility and food intake and the novel activ ingredients
CA2480765A1 (en) Animal composition
EP0792586A3 (en) Food products containing bacteria with cholesterol lowering activity
AR007155A1 (en) PROCESSED GLOBIN PRODUCTS AND METHODS FOR THEIR PREPARATION, AND EDIBLE PRODUCTS CONTAINING SUCH PROCESSED GLOBIN
ATE42177T1 (en) COMPOSITIONS SUITABLE FOR IMpartING BUTTER AND ANIMAL CHARACTERISTICS, PROCESS FOR THEIR PREPARATION.
DE69209453D1 (en) Process for making a low-fat spread

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150423

MKLA Lapsed

Effective date: 20150423